Lu Min, Merali Salim, Gordon Ronald, Jiang Jiandong, Li Yan, Mandeli John, Duan Xunbao, Fallon John, Holland James F
Mount Sinai School of Medicine, New York, NY, USA.
Genes Cancer. 2011 Oct;2(10):985-92. doi: 10.1177/1947601911436199.
Cardiac toxicity is a major limitation in the use of doxorubicin (and related anthracyclins). ON 1910.Na (Estybon, Rogersitib, or 1910), a substituted benzyl styryl sulfone, is equally active as doxorubicin against MCF-7 human mammary carcinoma xenografted into nude mice. 1910 augments the antitumor activity of doxorubicin when given simultaneously. Furthermore, when given in combination, 1910 protects against cardiac weight loss and against morphological damage to cardiac tissues. Doxorubicin induces inactivation of glucose response protein 78 (GRP78), a principal chaperone that serves as the master regulator of the unfolded protein response (UPR). Inactivated GRP78 leads to an increase in misfolded proteins, endoplasmic reticulum (ER) stress, activation of UPR sensors, and increased CHOP expression. 1910 prevents the inactivation of GRP78 by doxorubicin, and the combination, while more active against the tumor, protects against cardiac weight loss.
心脏毒性是使用阿霉素(及相关蒽环类药物)的主要限制因素。ON 1910.Na(Estybon、Rogersitib或1910),一种取代苄基苯乙烯基砜,在对移植到裸鼠体内的MCF - 7人乳腺癌异种移植瘤的作用上与阿霉素活性相当。1910与阿霉素同时给药时可增强其抗肿瘤活性。此外,联合使用时,1910可防止心脏重量减轻以及心脏组织的形态学损伤。阿霉素会诱导葡萄糖反应蛋白78(GRP78)失活,GRP78是一种主要的伴侣蛋白,作为未折叠蛋白反应(UPR)的主要调节因子。失活的GRP78会导致错误折叠蛋白增加、内质网(ER)应激、UPR传感器激活以及CHOP表达增加。1910可防止阿霉素导致的GRP78失活,并且这种联合用药在对肿瘤更具活性的同时,还能防止心脏重量减轻。